Detalhe da pesquisa
1.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Blood
; 142(10): 878-886, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319435
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
3.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood
; 138(6): 427-438, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827139
4.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289656
5.
A roadmap for clinical trial design in marginal zone lymphoma.
Am J Hematol
; 97(11): 1398-1403, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36030403
6.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood
; 134(15): 1238-1246, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331918
7.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Blood
; 134(14): 1144-1153, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409671
8.
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood
; 134(7): 626-635, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262783
9.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
10.
Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Blood
; 131(15): 1689-1697, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500170
11.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood
; 132(25): 2639-2642, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266774
12.
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Blood
; 132(10): 1013-1021, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30049811
13.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Blood
; 131(16): 1805-1808, 2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386196
14.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 131(11): 1183-1194, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229594
15.
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Oncologist
; 24(1): 86-95, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30082490
16.
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Blood
; 130(3): 267-270, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490569
17.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood
; 130(20): 2196-2203, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28874350
18.
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.
Am J Hematol
; 94(5): 585-596, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30784098
19.
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
Biol Blood Marrow Transplant
; 24(10): 2133-2138, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909154
20.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458003